
Sign up to save your podcasts
Or


Ovid Therapeutics Chairman Jeremy Levin talks with Scrip about how the US should view its biotech sector as a strategic national asset and urges the venture capital sector to place more emphasis on supporting early and innovative science.
By Norstella4.1
2828 ratings
Ovid Therapeutics Chairman Jeremy Levin talks with Scrip about how the US should view its biotech sector as a strategic national asset and urges the venture capital sector to place more emphasis on supporting early and innovative science.

1,290 Listeners

1,713 Listeners

4,420 Listeners

406 Listeners

154 Listeners

1,036 Listeners

837 Listeners

337 Listeners

1,320 Listeners

6,097 Listeners

1,281 Listeners

34 Listeners

678 Listeners

21 Listeners

170 Listeners